lobeglitazone/sitagliptin (CKD-396) / Chong Kun Dang - LARVOL DELTA

From Separation to Safety Prediction: Validated RP-HPLC Method for Simultaneous Estimation of Sitagliptin and Lobeglitazone, LC-MS/MS Identification of Degradant Products, and In Silico Safety Profiling. (PubMed, Biomed Chromatogr) - "In silico ADMET and toxicity profiling predicted high gastrointestinal absorption for all degradation products, with PI-1 and PI-2 flagged for carcinogenicity and all except PI-3 showing nephrotoxicity. This integrated analytical-computational approach provides a reliable tool for quality control and safety assessment of this antidiabetic formulation."

Journal • Diabetes • Metabolic Disorders

A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396 (clinicaltrials.gov) - P1; N=26; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial